Illustrative image.
Blenrep
Belantamab Mafodotin
$41150.00
100mg · 1 bottle
BrandBranded medicine· By GlaxoSmithKline
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningOcular toxicity
BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.
Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.
Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).
About Blenrep
Overview
Blenrep contains belantamab mafodotin, an antibody linked to a cell-killing medicine. It is used with bortezomib and dexamethasone to treat adults with multiple myeloma that has returned or has not responded to treatment, after at least two previous lines of therapy including a proteasome inhibitor and an immunomodulatory agent. It works by attaching to a protein called BCMA on myeloma cells and releasing a substance inside them that disrupts cell division and causes cell death.
What it treats
Blenrep is used with bortezomib and dexamethasone to treat adults with multiple myeloma that has returned or has not responded to treatment, after at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Safety information
Side effects
Common side effects reported when Blenrep is used with bortezomib and dexamethasone include reduced vision even with corrective lenses, changes to the cornea, blurred vision, dry eyes, sensitivity to light, a feeling of something in the eye, eye irritation or pain, cataracts, upper respiratory tract infections, liver toxicity, diarrhea, fatigue, pneumonia and COVID-19. Contact your doctor about vision changes or other eye symptoms, as eye toxicity can be serious. Other serious effects include low platelet counts, liver toxicity and pneumonia. Severe blood test abnormalities can include low platelets, lymphocytes, neutrophils, white blood cells or hemoglobin, and increased gamma-glutamyl transferase, a liver-related enzyme. Blood counts should be checked before and periodically during treatment. Blenrep can harm an unborn baby. Use effective contraception and contact your doctor if you become pregnant during treatment.
FDA boxed warning
Ocular toxicity
BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.
Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.
Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The label lists no formal contraindications. Blenrep requires monitoring for low platelet counts (thrombocytopenia). Complete blood counts should be checked before treatment and periodically during treatment. Depending on severity, the prescriber may pause treatment or reduce the dose. Blenrep can harm an unborn baby. Patients should be advised of this risk and use effective contraception. Do not breastfeed during treatment.
Using Blenrep
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place with the bottle tightly closed, away from direct light and moisture. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label BLENREP (BELANTAMAB MAFODOTIN) INJECTION, POWDER, FOR SOLUTION [GLAXOSMITHKLINE LLC] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00